{"id":902,"date":"2003-07-01T12:02:00","date_gmt":"2003-07-01T10:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/cholesterinsynthese-hemmer-prinzipiell-bei-diabetes-neue-ergebnisse-der-mrc-bhf-heart-protection-study"},"modified":"2022-03-17T14:10:28","modified_gmt":"2022-03-17T13:10:28","slug":"cholesterinsynthese-hemmer-prinzipiell-bei-diabetes-neue-ergebnisse-der-mrc-bhf-heart-protection-study","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/cholesterinsynthese-hemmer-prinzipiell-bei-diabetes-neue-ergebnisse-der-mrc-bhf-heart-protection-study","title":{"rendered":"Cholesterinsynthese-Hemmer prinzipiell bei Diabetes? Neue Ergebnisse der MRC\/BHF Heart Protection Study"},"content":{"rendered":"<p>Die MRC\/BHF Heart Protection Study (HPS) untersuchte an einer gro\u00dfen Studienpopulation (n = 20536) den Nutzen einer Cholesterinsynthese(CSE)-Hemmer-Therapie mit Simvastatin (Denan, Zocor u.a.) bei kardiovaskul\u00e4ren Risikogruppen. Es wurde nach einer 5j\u00e4hrigen Therapie eine geringere Sterblichkeit mit dem CSE-Hemmer ermittelt (12,9% vs. 14,7%; Number needed to treat = NNT ca. 227\/Jahr; 1). Das Besondere an dieser [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die MRC\/BHF Heart Protection Study (HPS) untersuchte an einer gro\u00dfen Studienpopulation (n = 20536) den Nutzen einer Cholesterinsynthese(CSE)-Hemmer-Therapie mit Simvastatin (Denan, Zocor u.a.) bei kardiovaskul\u00e4ren Risikogruppen. Es wurde nach einer 5j\u00e4hrigen Therapie eine geringere Sterblichkeit mit dem CSE-Hemmer ermittelt (12,9% vs. 14,7%; Number needed to treat = NNT ca. 227\/Jahr; 1). Das Besondere an dieser [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[451,449,48,455,2315,453,456,2314,505,443],"class_list":["post-902","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-diabetes-mellitus","tag-hmg-coa-reduktase-hemmer","tag-hps-studie","tag-hypercholesterinaemie","tag-lipidsenker","tag-mrc-bhf-hps-studie","tag-simvastatin","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=902"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/902\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}